Home Applications 021602 Application 021602
Type NDA
Sponsor MILLENNIUM PHARMS Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 VELCADE BORTEZOMIB INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 3.5MG/VIAL Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N021602-001 VELCADE BORTEZOMIB 3.5MG/VIAL INJECTABLE / INTRAVENOUS, SUBCUTANEOUS AP RLD, RS 2003-05-13
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 1 matching rows.
Application-product, TE code table Application-product TE code N021602-001 AP
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 44 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N021602-001 VELCADE 3.5MG/VIAL INJECTABLE / INTRAVENOUS, SUBCUTANEOUS AP RLD, RS 2003-05-13 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N021602-001 VELCADE 3.5MG/VIAL INJECTABLE / INTRAVENOUS, SUBCUTANEOUS AP RLD, RS 2003-05-13 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N021602-001 VELCADE 3.5MG/VIAL INJECTABLE / INTRAVENOUS, SUBCUTANEOUS AP RLD, RS 2003-05-13 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N021602-001 VELCADE 3.5MG/VIAL INJECTABLE / INTRAVENOUS, SUBCUTANEOUS AP RLD, RS 2003-05-13 a50c72e98297…
Observed Orange Book normalized TE history# Observed Orange Book patent history# Patent history page 1 of 2 · 72 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N021602-001 6713446 2022-01-25 Drug substance, Drug product 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N021602-001 6958319 2022-01-25 Drug substance, Drug product 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N021602-001 6713446*PED 2022-07-25 Pediatric extension 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N021602-001 6958319*PED 2022-07-25 Pediatric extension 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N021602-001 6713446 2022-01-25 Drug substance, Drug product 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N021602-001 6958319 2022-01-25 Drug substance, Drug product 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N021602-001 6713446*PED 2022-07-25 Pediatric extension 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N021602-001 6958319*PED 2022-07-25 Pediatric extension 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N021602-001 6713446 2022-01-25 Drug substance, Drug product 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 N021602-001 6958319 2022-01-25 Drug substance, Drug product 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 N021602-001 6713446*PED 2022-07-25 Pediatric extension 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 N021602-001 6958319*PED 2022-07-25 Pediatric extension 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 N021602-001 6713446 2022-01-25 Drug substance, Drug product 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N021602-001 6958319 2022-01-25 Drug substance, Drug product 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N021602-001 6713446*PED 2022-07-25 Pediatric extension 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N021602-001 6958319*PED 2022-07-25 Pediatric extension 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 N021602-001 6713446 2022-01-25 Drug substance, Drug product bb7c543d1eb4…2022-03-09 01:35 UTC 2022-03 N021602-001 6958319 2022-01-25 Drug substance, Drug product bb7c543d1eb4…2022-03-09 01:35 UTC 2022-03 N021602-001 6713446*PED 2022-07-25 Pediatric extension bb7c543d1eb4…2022-03-09 01:35 UTC 2022-03 N021602-001 6958319*PED 2022-07-25 Pediatric extension bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N021602-001 6713446 2022-01-25 Drug substance, Drug product 782e0a99824c…2021-12-28 21:50 UTC 2021-12 N021602-001 6958319 2022-01-25 Drug substance, Drug product 782e0a99824c…2021-12-28 21:50 UTC 2021-12 N021602-001 6713446*PED 2022-07-25 Pediatric extension 782e0a99824c…2021-12-28 21:50 UTC 2021-12 N021602-001 6958319*PED 2022-07-25 Pediatric extension 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N021602-001 6713446 2022-01-25 Drug substance, Drug product 87673890dc5c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N021602-001 6958319 2022-01-25 Drug substance, Drug product 87673890dc5c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N021602-001 6713446*PED 2022-07-25 Pediatric extension 87673890dc5c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N021602-001 6958319*PED 2022-07-25 Pediatric extension 87673890dc5c…2021-03-12 10:30 UTC 2021-03 N021602-001 6713446 2022-01-25 Drug substance, Drug product 5aa47cf7b7d7…2021-03-12 10:30 UTC 2021-03 N021602-001 6958319 2022-01-25 Drug substance, Drug product 5aa47cf7b7d7…2021-03-12 10:30 UTC 2021-03 N021602-001 6713446*PED 2022-07-25 Pediatric extension 5aa47cf7b7d7…2021-03-12 10:30 UTC 2021-03 N021602-001 6958319*PED 2022-07-25 Pediatric extension 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N021602-001 6713446 2022-01-25 Drug substance, Drug product 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N021602-001 6958319 2022-01-25 Drug substance, Drug product 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N021602-001 6713446*PED 2022-07-25 Pediatric extension 8869cabd3fbd…2020-12-22 03:56 UTC 2020-12 N021602-001 6958319*PED 2022-07-25 Pediatric extension 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N021602-001 6713446 2022-01-25 Drug substance, Drug product c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N021602-001 6958319 2022-01-25 Drug substance, Drug product c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N021602-001 6713446*PED 2022-07-25 Pediatric extension c0c555d07b60…2020-11-12 02:37 UTC 2020-11 N021602-001 6958319*PED 2022-07-25 Pediatric extension c0c555d07b60…
Observed Orange Book exclusivity history# openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join VELCADE BORTEZOMIB Takeda Pharmaceuticals America, Inc. 1521d321-e724-4ffc-adad-34bf4f44fac7 2025-08-28 Warnings, Adverse reactions Exact identifier application applno (NDA): 021602 application number: NDA021602 ndc (product): 63020-049
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 9 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 63020-049 VELCADE bortezomib Millennium Pharmaceuticals, Inc. NDA Current 63020-049 VELCADE bortezomib Takeda Pharmaceuticals America, Inc. NDA Current 63020-049 VELCADE bortezomib Takeda Pharmaceuticals America, Inc. NDA Current 63020-049 VELCADE bortezomib Millennium Pharmaceuticals, Inc. NDA Current 63020-049 VELCADE bortezomib Takeda Pharmaceuticals America, Inc. NDA Current 63020-049 VELCADE bortezomib Takeda Pharmaceuticals America, Inc. NDA Current 63020-049 VELCADE bortezomib Millennium Pharmaceuticals, Inc. NDA Current 63020-049 VELCADE bortezomib Takeda Pharmaceuticals America, Inc. NDA Current 63020-049 VELCADE bortezomib Takeda Pharmaceuticals America, Inc. NDA Current